共 50 条
- [1] Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary nodepositive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199.BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 341 - 342Sparano, J. A.Wang, M.Martino, S.Jones, VPerez, E. A.Saphner, T.Wolff, A. C.Sledge, G. W.Wood, W. C.Davidson, N. E.
- [2] Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancerCANCER RESEARCH, 2015, 75Sparano, Joseph A.Zhao, FengminMartino, SilvanaLigibel, JenniferSaphner, ThomasWolff, Antonio C.Sledge, George W., Jr.Perez, Edith A.Wood, William C.Davidson, Nancy E.
- [3] Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trialLUNG CANCER, 2002, 35 (03) : 315 - 317Koumakis, GDemiri, MBarbounis, VVassilomanolakis, MGontikakis, EPamouksoglou, PDahabre, JEfremidis, AP
- [4] Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Iwase, S.Yamamoto, D.Kitamura, K.Odagiri, H.Teramoto, S.Ohtani, S.Doi, T.Kinebuchi, K.Kuroda, Y.Nagumo, Y.
- [5] Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 930 - 935Kelly, Catherine M.Green, Marjorie C.Broglio, KristineThomas, Eva S.Brewster, Abenaa M.Valero, VicenteIbrahim, Nuhad K.Gonzalez-Angulo, Ana M.Booser, Daniel J.Walters, Ronald S.Hunt, Kelly K.Hortobagyi, Gabriel N.Buzdar, Aman U.
- [6] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer:: results of the ERASME 3 studyBREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 343 - 350Cassier, Philippe A.Chabaud, SylvieTrillet-Lenoir, VeroniquePeaud, Pierre-YvesTigaud, Jean-DominiqueCure, HerveOrfeuvre, HubertSalles, BrunoMartin, ClaudeJacquin, Jean-PhilippeAgostini, CecileGuastalla, Jean-PaulPerol, DavidBachelot, Thomas
- [7] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 studyBreast Cancer Research and Treatment, 2008, 109 : 343 - 350Philippe A. CassierSylvie ChabaudVéronique Trillet-LenoirPierre-Yves PeaudJean-Dominique TigaudHervé CureHubert OrfeuvreBruno SallesClaude MartinJean-Philippe JacquinCecile AgostiniJean-Paul GuastallaDavid PérolThomas Bachelot
- [8] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5381 - 5387Jones, Stephen E.Savin, Michael A.Holmes, Frankie AnnO'Shaughnessy, Joyce A.Blum, Joanne L.Vukelja, SvetislavaMcIntyre, Kristi J.Pippen, John E.Bordelon, James H.Kirby, RobertSandbach, JohnHyman, William J.Khandelwal, PankajNegron, Angel G.Richards, Donald A.Anthony, Stephen P.Mennel, Robert G.Boehm, Kristi A.Meyer, Walter G.Asmar, Lina
- [9] Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:: The GEPARDUO Study of the German Breast GroupJOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2676 - 2685von Minckwitz, GRaab, GCaputo, ASchütte, MHilfrich, FBlohmer, JUGerber, BCosta, SDMerkle, EEidtmann, HLampe, DJackisch, Cdu Bois, AKaufmann, M
- [10] A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Loesch, D. M.Greco, F.O'Shaughnessy, J.Hainsworth, J. D.Vukelja, S. J.Sandbach, J.Boehm, K. A.Ilegbodu, D.Asmar, L.Robert, N. J.